AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02603133 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Three Good Things
Description: In this tool participants reflect on good things that happened that day during evenings across 10 days. Participants are also able to voluntarily share their good things and read other participants' good things through the nightly anonymous log. By savoring good moments from earlier that day, participants are thought to shift from the natural focus on what went poorly due to negativity bias1 to an appreciation for what went well. This shift in focus is thought to reduce rumination and depression symptoms. In prior research, 3GTs was found to increase happiness and decrease depression in internet participants.2 In prior cohorts of 3GTs, we saw improvements in burnout, depression symptoms, work-life balance, and happiness. Participants also report benefiting from viewing nightly Three Good Things logs of others.
Study NCT02603133 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Three Good Things
Description: In this tool participants reflect on good things that happened that day during evenings across 10 days. Participants are also able to voluntarily share their good things and read other participants' good things through the nightly anonymous log. By savoring good moments from earlier that day, participants are thought to shift from the natural focus on what went poorly due to negativity bias1 to an appreciation for what went well. This shift in focus is thought to reduce rumination and depression symptoms. In prior research, 3GTs was found to increase happiness and decrease depression in internet participants.2 In prior cohorts of 3GTs, we saw improvements in burnout, depression symptoms, work-life balance, and happiness. Participants also report benefiting from viewing nightly Three Good Things logs of others.
Study NCT02603133 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Gratitude
Description: In this tool participants are offered the opportunity to cultivate gratitude toward others through a guided gratitude letter writing exercise.2 Through expressing gratitude, we learn more about our vital connections to others, often in surprising and meaningful ways. Previous research has found that gratitude interventions increase well-being in a number of ways, particularly in boosting positive affect.
Study NCT02603133 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gratitude
Description: In this tool participants are offered the opportunity to cultivate gratitude toward others through a guided gratitude letter writing exercise.2 Through expressing gratitude, we learn more about our vital connections to others, often in surprising and meaningful ways. Previous research has found that gratitude interventions increase well-being in a number of ways, particularly in boosting positive affect.
Study NCT02603133 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Random Acts of Kindess
Description: In this tool, participants report kind acts that they have committed, received, and/or witnessed, each day. By committing random acts of kindness participants experience a boost of positive emotions, and report lower negative affect. Recipients of acts of kindness benefit as well.
Study NCT02603133 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Random Acts of Kindess
Description: In this tool, participants report kind acts that they have committed, received, and/or witnessed, each day. By committing random acts of kindness participants experience a boost of positive emotions, and report lower negative affect. Recipients of acts of kindness benefit as well.
Study NCT03219463 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ginger
Description: 3g ginger powder supplement once a day with meals (preferably in the morning) for a duration of 8 weeks. Powder can be mixed with juice or water.
Study NCT04597060 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermomechanical system with corticosteroids
Description: The device in this study using Novoxel - Tixel®
Study NCT04597060 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: corticosteroid injection
Description: corticosteroid injection using TA 10mg/ml
Study NCT01167985 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IABN
Description: Patients with single canal teeth diagnosed with infected pulp and periapical lesion, and need root canal treatment, will be asked to participate in the study. The study group will have their canal sealed with endodontic sealer + the nanoparticles. The control group will have their canal sealed with the conventional sealer alone. The patients will be invited to 4 follow ups during which a clinical and radiological examinations will be performed.While preparing the post, a sample of the sealer will be taken to evaluation in the lab.
Study NCT01167985 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IABN
Description: patients with molar teeth diagnosed with healthy pulp or irreversible pulpitis, and need root canal treatment, will be asked to participate in the study. After cleaning the teeth following a standard protocol, a sterile cotton wool will be placed in the pulp chamber. provisional restoration with and without nanoparticles will seal the teeth between apointments. After a month the cotton wool will be taken out and tansferred to the laboratory. The root canal treatment will continue following the standard protocol.
Study NCT03403387 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GlutenShield
Description: combination probiotic, prebiotic, and enzyme supplement
Study NCT03403387 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Avicel (cellulose) and bentonite powder
Study NCT00174772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel and cisplatin followed by concurrent chemoradiotherapy with docetaxel and cisplatin + radiotherapy
Description: docetaxel (75mg/m2, IV, Day 1) and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles, followed by concurrent chemoradiotherapy with docetaxel (20 mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy
Study NCT00174772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel and cisplatin + radiotherapy followed by docetaxel and cisplatin
Description: docetaxel (20mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy followed by docetaxel and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles.
Study NCT01230203 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Computed tomography scan versus color duplex ultrasound
Description: Computed tomography scan versus color duplex ultrasound
Study NCT02700087 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ranitidine or famotidine
Description: Patients with symptomatic laryngomalacia will receive ranitidine, famotidine, or placebo medications in order to see if these medications help their symptoms to resolve.
Study NCT02700087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranitidine or famotidine
Description: Patients with symptomatic laryngomalacia will receive ranitidine, famotidine, or placebo medications in order to see if these medications help their symptoms to resolve.
Study NCT02700087 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients with symptomatic laryngomalacia who meet inclusion criteria will be randomized to receive placebo, ranitidine or famotidine, in order to see if these medications help their symptoms to resolve.
Study NCT05519332 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: percutaneous vertebral-disc plasty
Description: percutaneous vertebroplasty combined percutaneous cement discoplasty
Study NCT01513200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH)
Description: UFH solution for infusion Initially 60U/kg bolus followed by intravenous infusion (12U/kg/hr) for approximately 11 hours
Study NCT01513200 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Unfractionated heparin (UFH)
Description: UFH solution for infusion Initially 60U/kg bolus followed by intravenous infusion (12U/kg/hr) for approximately 11 hours
Study NCT01513200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendavia
Description: Bendavia for infusion Constant intravenous infusion (Bendavia 0.25mg/kg/hr) for 4 hours
Study NCT01513200 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline (0.9%, sterile, for infusion)
Description: Saline (placebo) Constant IV infusion for 4 hours
Study NCT02069340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: Given IV
Study NCT02069340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT02677311 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood draw
Description: Blood draws will be performed immediately prior to GnRHa treatment and at 6 and 12 months following treatment completion
Study NCT02677311 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pelvic Ultrasound
Description: Pelvic ultrasound will be performed immediately prior to GnRHa treatment and at 6 and 12 months following treatment completion
Study NCT00156156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil
Description: Asoprisnil 10 mg Tablet, oral Daily for up to 2 years
Study NCT00156156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil
Description: Asoprisnil 25 mg Tablet, oral Daily for up to 2 years
Study NCT03907839 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinical trials
Description: examined two type of training on cognitive parameters for COPD patients
Study NCT03907839 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: clinical trials
Description: examined two type of training on cognitive parameters for COPD patients
Study NCT00527488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Two doses of 16 mg each administered as two administrations (separated by 14 days) will be evaluated for 42 days.
Study NCT00527488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: One dose of 32 mg administered as a single administration will be evaluated for 42 days.
Study NCT00527488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Two doses of 32 mg each administered as two administrations (separated by 14 days) will be evaluated for 42 days.
Study NCT00527488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: One dose of 64 mg administered as a single administration will be evaluated for 42 days.
Study NCT01958827 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Adalimumab pre-filled syringe, administered by subcutaneous injection.
Study NCT03343418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desmopressin
Description: Desmopressin is to be administered as an intravenous infusion after discontinuation of cardiopulmonary bypass and administration of protamine. Subjects are to be given desmopressin 0,3 microgram.kg-1. After desmopressin infusion, bleeding treatment will follow the predefined standardized treatment regimen.
Study NCT00670696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapydan
Description: Topical anaesthetic plaster
Study NCT00670696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tetracaine gel
Description: Topical tetracaine gel
Study NCT01013974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719 250 μg
Description: Strip 1 of the dry powder inhaler will contain GSK573719 250 μg micronized drug with lactose along with magnesium stearate. Strip 2 will contain lactose powder along with magnesium stearate. It will be available as dry off white powder for inhalation.
Study NCT01013974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719 500 μg
Description: Strip 1 of the dry powder inhaler will contain GSK573719 500 μg micronized drug with lactose along with magnesium stearate. Strip 2 will contain lactose powder along with magnesium stearate. It will be available as dry off white powder for inhalation.
Study NCT01013974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719 1000 μg
Description: Strips 1 and 2 of the dry powder inhaler will contain 500 μg each of GSK573719 micronized drug with lactose along with magnesium stearate. It will be available as dry off white powder for inhalation.
Study NCT01013974 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK573719 matching Placebo
Description: Strip 1 and 2 of the dry powder inhaler will contain lactose powder along with magnesium stearate. It will be available as dry off white powder for inhalation.
Study NCT00648401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil Hydrochloride Extended-Release Capsules, 300 mg
Description: 300mg, single dose fed
Study NCT02603133 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Awe
Description: This tool provides participants the opportunity to recount in detail one of their own experiences of awe, and encourages them to be on the lookout for new ones (even minor examples) over a few days. When we experience awe, our sense of time expands, we are kinder to others, we experience higher life satisfaction, and we prefer experiences over material things.
Study NCT00648401 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verelan® PM Extended-Release Capsules, 300 mg
Description: 300mg, single dose fed
Study NCT03186326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX regimen
Description: A course of treatment every 14 days~Oxaliplatin: 85 mg/m² IV over 2 hours Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) IV over 2 hours 5FU bolus: 400 mg/m² IV bolus over 10 minutes in 100 ml 0.9% NaCl 5FU continuous: 2,400 mg/m² in NaCl 0.9% in IV over 46 hours
Study NCT03186326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI Protocol
Description: A course of treatment every 14 days~Irinotecan: 180 mg/m² IV over 1H30 Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) IV over 2 hours 5FU bolus: 400 mg/m² IV bolus over 10 minutes in 100 ml 0.9% NaCl 5FU continuous: 2,400 mg/m² in NaCl 0.9% in IV over 46 hours
Study NCT03186326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: A course of treatment every 14 days. Premedication obligatory with antihistamines and paracetamol (example: 25-50 mg diphenhydramine and 500-650 mg paracetamol) IV, approximately 30 to 60 minutes before each dose of avelumab.~Then:~Avelumab: 10 mg/kg IV in 1 hour diluted with 0.9% saline solution; alternatively a 0.45% saline solution can be used if needed
Study NCT03186326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Panitumumab
Description: Administered at 6 mg/Kg
Study NCT03186326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Administered at 500 mg/m²
Study NCT03186326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Administered at 5 mg/Kg
Study NCT03186326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Administered at 4 mg/Kg
Study NCT03726021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan,Oxaliplatin, and S1
Description: Drug: Irinotecan is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.~Drug: Oxalipatin Oxaliplatin is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells~Drug: S1 is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells
Study NCT01372358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CIPRO®XR
Description: Ciprofloxacin 1000 mg Tablets Dr. Reddy's Laboratories Limited
Study NCT01372358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIPRO®XR
Description: Ciprofloxacin 1000 mg Tablets Dr. Reddy's Laboratories Limited
Study NCT00462644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RSI sedation with etomidate/succinylcholine
Description: etomidate 0.3 mg/kg IV plus succinylcholine 1 mg/kg IV
Study NCT00462644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RSI sedation with fentanyl/midazolam/succinylcholine
Description: 100 micrograms fentanyl IV, plus 5 mg midazolam IV, plus 1 mg/kg succinylcholine IV
Study NCT02603133 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Awe
Description: This tool provides participants the opportunity to recount in detail one of their own experiences of awe, and encourages them to be on the lookout for new ones (even minor examples) over a few days. When we experience awe, our sense of time expands, we are kinder to others, we experience higher life satisfaction, and we prefer experiences over material things.
Study NCT02603133 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 1 Good Chat
Description: This tool uses the latest research on cultivating relationships and increasing social connection. Feeling socially connected is linked to health and well-being outcomes, including longevity.6 The 1 Good Chat tool asks participants to reflect on good conversations and to note the prosocial behaviors that he/she and the other person engaged in
Study NCT00438867 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Ad5FGF-4
Description: Adenovirus serotype-5 mediated human fibroblast growth factor-4 gene transfer
Study NCT00438867 — intervention group
Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control group
Study NCT03407261 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: micro-osteoperforations
Description: Three vertical micro-osteoperforations, using Excellerator, in the buccal extracted site were executed following the aseptic procedure and local anesthesia
Study NCT01404611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DF289
Description: Ear drops
Study NCT01404611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DF277
Description: Ear drops
Study NCT01404611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DF289 plus DF277
Description: Ear drops
Study NCT03816891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vixarelimab
Description: solution for injection
Study NCT03816891 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: solution for injection
Study NCT02868580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triumeq
Description: Triumeq, a combination of dolutegravir, abacavir and lamivudine is an anti-retroviral therapy indicated for people with HIV-1 infection.
Study NCT00550173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed
Description: 500 milligrams per meter squared (mg/m\^2), intravenous (IV), every (q) 21 days until progression or unacceptable toxicity develops
Study NCT00550173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 milligrams per meter squared (mg/m\^2), intravenous (IV), every (q) 21 days until progression or unacceptable toxicity develops
Study NCT00550173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erlotinib
Description: 150 mg, orally, once daily until progression or unacceptable toxicity develops
Study NCT00550173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: 150 mg, orally, once daily until progression or unacceptable toxicity develops
Study NCT02850328 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: examination of muscle function and MVC in weightlessness
Description: MVC tested during three different tasks: (1) leg press, (2) plantarflexion and (3) grip strength.~parameters of muscle function that can be easily implemented in parabolic flight:~* Rate of force development~* Electromyographic activity~* Ultrasound measure: fascicle length and pennation angle of the gastrocnemius medialis muscle~* Superimposed twitch torque (M-waves at rest and V-waves in MVC conditions)~* Maximum voluntary activation capacity (%VA): %VA = (1-\[torque superimposed twitch/torque resting twitch\])\*100%.
Study NCT01081353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic Acid (Aspirin BAY1019036)
Description: One tablet of new formula Aspirin under fasting conditions
Study NCT01081353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alka Seltzer Extra Strength
Description: One effervescent tablet under fasting conditions
Study NCT01081353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin Migraine
Description: One effervescent tablet under fasting conditions
Study NCT01081353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin Aspro
Description: One effervescent tablet under fasting conditions
Study NCT04425993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosorbide Dinitrate 5 MG
Description: All patients without contraindications should receive sublingual isosorbide dinitrate tablet within 5 minutes before ERCP.
Study NCT04425993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isosorbide Dinitrate 5 MG
Description: All patients without contraindications should receive sublingual isosorbide dinitrate tablet within 5 minutes before ERCP.
Study NCT04425993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin 100 MG
Description: All patients without contraindications should receive rectal indomethacin within 30 min before ERCP.
Study NCT04425993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin 100 MG
Description: All patients without contraindications should receive rectal indomethacin within 30 min before ERCP.